Sigyn Therapeutics, Inc. announced the appointment of Alexander S. Yevzlin, MD, FASN to its Scientific Advisory Board. Dr. Yevzlin's considerable extracorporeal industry experience and insight is expected to contribute to the clinical advancement of Sigyn Therapy. Sigyn Therapy is an extracorporeal blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 USD | +5.00% | +5.00% | +10.99% |
20/02 | Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer | CI |
Chiffre d''affaires - Rate of surprise
- Stock Market
- Equities
- SIGY Stock
- News SIGN THERPAR
- Sigyn Therapeutics, Inc. Appoints Alexander S. Yevzlin to its Scientific Advisory Board